InMed Pharmaceuticals Inc. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
InMed's shareholders' equity fell to $1,075,007 as of June 30, 2026, below Nasdaq's $2,500,000 minimum requirement, driven by merger-related transaction expenses, BayMedica wind-down costs, and operating losses. The company has 45 days to submit a compliance plan; Nasdaq may grant a 180-day extension. The pending merger with Mentari (expected Q4 2026) is projected to inject ~$490M in gross proceeds, which management expects will restore compliance and prevent delisting.
Why this rating
Company market cap ~$3M; equity shortfall of $1.4M is 47% of market value. Delisting risk is existential threat. Merger is lifeline but execution uncertain and contingent on shareholder approval.
Price action (we called it negative)
before filing · preread $1.36 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.